Edwards Lifesciences (NYSE:EW) Issues FY 2026 Earnings Guidance

Posted by Brian Himes on Jul 25th, 2026

Edwards Lifesciences (NYSE:EW – Get Free Report) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 2.950-3.050 for the period, compared to the consensus EPS estimate of 3.010. The company issued revenue guidance of $6.6 billion-$6.9 billion, compared to the consensus revenue estimate of $6.7 billion. Edwards Lifesciences also updated its Q3 2026 guidance to 0.710-0.770 EPS.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of research analyst reports. Barclays reiterated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Mizuho raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Robert W. Baird lifted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.55.

Check Out Our Latest Stock Analysis on EW

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $82.67 on Friday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $96.29. The business has a fifty day simple moving average of $87.73 and a 200 day simple moving average of $83.88. The firm has a market cap of $47.60 billion, a price-to-earnings ratio of 47.51, a P/E/G ratio of 2.10 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter last year, the firm earned $0.67 earnings per share. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts predict that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $91.70, for a total value of $56,762.30. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,577 shares of company stock worth $3,855,527 in the last three months. 0.31% of the stock is owned by insiders.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $27,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the third quarter worth about $25,000. Rakuten Securities Inc. boosted its stake in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Kelleher Financial Advisors acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at approximately $50,000. Finally, Chapman Financial Group LLC bought a new position in Edwards Lifesciences in the 2nd quarter worth approximately $63,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.